Opendata, web and dolomites

MetaboMARKER

A metabolism-based prognostic biomarker for prostate cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaboMARKER project word cloud

Explore the words cloud of the MetaboMARKER project. It provides you a very rough idea of what is the project "MetaboMARKER" about.

co    resist    treating    potentially    impose    followed    patients    mortality    guidelines    framework    least    clinicians    prognostic    cancermetab    castration    age    sixth    prone    prostatectomy    urgently    informs    frequently    last    progressively    biomarker    vs    chemical    predominantly    prostate    fraction    harbouring    pc    exhibit    western    therapeutic    plan    life    line    therapies    public    sources    risk    lack    chemotherapy    cancer    men    protected    final    localized    affordable    erc    treatments    recurrent    336343    disease    exhibited    resides    stg    efficient    tumour    morbidities    obesity    responders    strategies    patent    treatment    intensive    capacity    metabomarker    localised    health    recurrence    endangering    diagnosis    societies    tools    first    15    enrolled    secondary    pressure    funds    uncertain    strategy    profound    differentiate    poc    commercialization    costly    lives    progress    therapy    metastasize    escapers    employ    radiotherapy    decade    prevalent    subsequent    fail   

Project "MetaboMARKER" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 150˙000.00

Map

 Project objective

Prostate cancer (PC) is the most prevalent tumour type among men. The fraction of patients that exhibit disease recurrence can reach 15% and they face an uncertain future, since this type of tumour is prone to resist to subsequent therapeutic strategies. Current guidelines for treatment of PC include prostatectomy or radiotherapy as first line therapy for localized disease, and chemical castration followed by chemotherapy for recurrent PC. The lack of capacity to identify therapy responders vs. escapers in PC is one of the sources for its important mortality. The challenge resides in providing clinicians with a robust and affordable biomarker that informs about the success of first line therapy in localised PC, and that allows them to employ more intensive therapeutic strategies in high-risk patients. The development of such prognostic tools is urgently needed, since western societies are facing profound changes in the major PC risk factors, including age and obesity. Last, but not least, the cost of treating PC will progressively impose strong pressure in the public health system. In addition, patients that fail first-line therapy can be enrolled in subsequent therapies for up to a decade, and given their advance age (PC predominantly presents in the sixth decade of life) they frequently present endangering and costly co-morbidities and secondary effects. MetaboMARKER, a novel biomarker developed in the framework of the ERC-StG-336343-CancerMetab and already protected under a European patent, is able to differentiate patients harbouring a PC that would progress and potentially metastasize, from those that exhibited a disease that would not likely be a risk to their lives. Thus, MetaboMARKER may contribute to more efficient diagnosis, improved treatments and better distribution of funds in disease management. The aim of the present PoC is to further develop the final biomarker for its commercialization and define the best exploitation strategy plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METABOMARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METABOMARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

FunDiT (2019)

Functional Diversity of T cells

Read More